Highly Anticipated Alzheimer's Drug Fails

A study of one of the most anticipated experimental drugs for Alzheimer's disease failed to help patients with mild to moderate symptoms, according to Reuters. As a result, Pfizer Inc and Johnson & Johnson said they would discontinue all other studies of the drug bapineuzumab—which, if successful, would have been the first drug to fight the progression of the debilitating memory-robbing disease. Attention will now turn to a similar drug being developed by Eli Lilly & Co called solanezumab, which is also considered a long shot; late-stage test results are expected to be released later this year.

Read More

Contact Us